Saturday, March 26, 2011
What Do A Lipomas Look Like
A new treatment for
reduce brain lesions
in these patients
A new therapy for multiple sclerosis yet under investigation has shown that it can achieve a significant reduction in recurrent disease type, as it manages to decrease brain injury and thus, the risk of relapse.
This follows from a Phase II with the new drug known as ocrelizumab, whose effectiveness has been proven in more than 200 patients over 24 weeks.
Ocrelizumab has shown that it can achieve a significant reduction in recurrent disease type, as it manages to decrease brain injury and thus, the risk of relapse
The total reduction of brain lesions detected by MRI (MRI) was significantly higher, reaching 96 percent by using 2,000 milligrams and 89 percent with 600 mg compared to placebo.
The disease activity was also determined from the annual relapse rate (TAR), ie, the relapse rate or exacerbations per patient-year. At week 24, HAART was significantly lower compared with the placebo group, reaching the reduction of 73 percent to 2,000 milligrams and 80 percent to 600 milligrams.
addition, both doses were well tolerated ocrelizumab, in general, not any opportunistic infection was reported, while serious adverse events (SAEs) were similar in all treatment groups.
reactions associated with infusion during the first infusion, mild to moderate predominantly ocrelizumab were more common (34.5 and 43.6 per cent) than with placebo (9.3 percent). Now, with a second infusion of ocrelizumab decreased the reported cases, which were comparable to those described initially with placebo.
as underlined by Dr. Ludwig Kappos, Department of Neurology, University Hospital Basel (Switzerland), this efficiency is the most remarkable seen in a study of relapsing-remitting phase II, so that may have the potential to benefit patients with this disease.
Posted by admin at 12:34 PM